KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CRISPR Therapeutics AG (CRSP) Assets Average: 2016-2025

Historic Assets Average for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $2.1 billion.

  • CRISPR Therapeutics AG's Assets Average fell 6.98% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 6.98%. This contributed to the annual value of $2.2 billion for FY2024, which is 0.02% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Assets Average stood at $2.1 billion, which was up 1.89% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Assets Average ranged from a high of $2.9 billion in Q3 2021 and a low of $1.9 billion during Q1 2021.
  • Over the past 3 years, CRISPR Therapeutics AG's median Assets Average value was $2.2 billion (recorded in 2023), while the average stood at $2.2 billion.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Assets Average spiked by 136.51% in 2021, and later dropped by 17.53% in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Assets Average (Quarterly) stood at $2.8 billion in 2021, then declined by 17.53% to $2.3 billion in 2022, then fell by 6.09% to $2.2 billion in 2023, then increased by 4.21% to $2.2 billion in 2024, then dropped by 6.98% to $2.1 billion in 2025.
  • Its Assets Average stands at $2.1 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.2 billion for Q1 2025.